| abstract |
This invention deals with compounds of formula (I) or (II), their preparation and their use in methods and compositions to treat certain conditions. In formulas (I) and (II), X is halogen, H, C1-4 alkyl; or OR5, where R5 is H, perfluoroC1-4alkyl, fluoroC1-4alkyl, perdeuteroalkylC1-4, C1-20alkyl, C4-20alkylalkyl, C2-20carbonitriloalkyl, C3-22carboalkoxy, C3-20alkenyl, C3alkynyl -20, C9-20 aralkyl, C9-20 aralkenyl, C9-20 aralkynyl, C2-20 hydroxyalkyl, ar C8-20 yloxyalkyl, C7-20 pyridylalkyl, or C6-20 pyrrylalkyl; Y is H or halogen; Z is H, halogen, cyano, aryl, aralkyl, C8-20 arylquinyl, or C2-20 alkamide; R, in both cases, is H, halogen, or C1-4 alkyl; G is a divalent methylene, ethylene, alkenyl fraction, R1 is H, C1-4alkyl or benzyl; and R2 is C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C2-4 alkoxyalkyl, C1-4 trifluoromethylalkyl, C2-8alkylthioalkyl or NR3R4, wherein R3 and R4 are independently selected from H and C1-4 alkyl, but R3 and R4 cannot both be H. Furthermore, the invention includes isotopically labeled variants of the disclosed compounds, particularly the disclosed compounds, particularly the radioiodinated compounds in which a radioactive isotope of iodine, such as I 122, I 1233 or I 131, is has incorporated. The compounds of the present invention possess affinity for endogenous pineal hormone receptor, melatonin, as determined in a receptor binding assay, and exhibit antagonistic activity as determined by a functional assay. One or more compounds of the invention can be mixed with pharmaceutically acceptable amounts of one or more conventional excipients to produce a formula to be administered by the desired route. Generally, compositions including compounds of the |